Thaum Lub Peb Hlis 21, raws li CDE lub vev xaib raug cai, Kangpu Biopharmaceuticals, Ltd. (tom qab no hu ua "Kangpu") tau txais daim ntawv tso cai los ua cov kev sim tshuaj rau KPG-818 tshuaj ntsiav, Chav Kawm 1 chemotherapy, nrog rau qhia txog kev mob lupus erythematosus.
Immunomodulators yog ib chav kawm ntawm cov tshuaj uas tswj lub cev tiv thaiv kab mob thiab qhib lossis inhibit lub cev tiv thaiv kab mob, thiab tuaj yeem siv kho mob los kho ntau yam kab mob tiv thaiv kab mob. Nyob rau hauv xyoo tas los no, nrog rau kev tshawb fawb tob txog cov kab mob tiv thaiv kab mob, tau tshawb pom ib tiam tshiab ntawm cov tshuaj tiv thaiv kab mob uas muaj txiaj ntsig zoo thiab muaj kev nyab xeeb dua.
KPG-818, tsim thiab tsim los ntawm Kangpu, yog ib tiam tshiab ntawm qhov ncauj molecular gel immunomodulatory tshuaj uas koom nrog E3 ubiquitin ligase complex CRL4-CRBN modulator. Raws li cov ntaub ntawv pej xeem, KPG-818 nthuav tawm qhov kev sib raug zoo siab rau lub hom phiaj CRBN khi, thiab muaj peev xwm ua tau zoo degrade cov zinc-ntiv tes transcription yam tseem ceeb Aiolos (IKZF3) thiab Ikaros (IKZF1), uas muaj feem cuam tshuam nrog kev txhim kho thiab Kev loj hlob ntawm B-lymphocytes, thiab kom tswj tau cov kev qhia theem ntawm cytokines, xws li TNF-alpha, IL-6, IL-2, IL-10, thiab lwm yam.
Tam sim no, KPG-818 tab tom tab tom ntsib ntau qhov kev sim tshuaj txawv teb chaws, suav nrog Phase I kev sim tshuaj rau cov qog nqaij hlav hematological thiab Phase Ib/IIa kev sim tshuaj rau cov kab mob lupus erythematosus. Thaum Lub Ob Hlis Ntuj xyoo no, Kangpu nthuav tawm ib daim ntawv tshaj tawm txog cov ntaub ntawv ua tau zoo ntawm KPG-818 hauv cov qauv tsiaj rau kev kho mob Crohn's disease ntawm 19th ECCO Congress, thiab tshaj tawm tias nws yuav raug xa mus rau US Phase II kev sim tshuaj.
Cov lus pom zoo rau KPG-818 hauv Suav teb yog kab mob lupus erythematosus, thiab Kangpu tuaj yeem ua qhov kev sim tshuaj ntxiv rau KPG-818 yav tom ntej.
Kev tsom mus rau kev tsim cov tshuaj tshiab rau kev mob qog noj ntshav, kab mob autoimmune, mob thiab lwm qhov chaw kho mob, Kangpu muaj lub ntiaj teb ua tus tswv patents ntawm cov tiam tshiab ntawm molecular gel-protein ubiquitination thiab nws cov thev naus laus zis degradation, xws li NeoMIDES®, SelPDEiS®, X -SYNERGY®, thiab lwm yam. Tam sim no, raws li cov thev naus laus zis saum toj no, Kangpu tau ua tiav cov kav dej nplua nuj hauv kev tshawb fawb thiab kev tsim kho.
Ntawm lawv, KPG-121 yog ib tiam tshiab CRBN E3 ubiquitin ligase complex CRL4CRBN regulator, uas muaj inhibitory cell proliferation kev ua ub no raws li anti-angiogenic kev ua si, thiab nyob rau tib lub sij hawm muaj peev xwm txhim kho lub cev immunomodulatory muaj nuj nqi. Thaum Lub Kaum Ib Hlis 2023, Kangpu nthuav tawm cov ntaub ntawv xov xwm ntawm KPG-121 ntawm 2023 Society for Immunotherapy of Cancer Lub Rooj Sib Tham Txhua Xyoo thiab tshaj tawm tias nws yuav pib lub ntiaj teb, ntau lub chaw kho mob Phase II / III sau npe tshuaj ntsuam xyuas ntawm KPG{{8 }} rau kev kho mob ntawm metastatic desmoplasia-resistant prostate cancer.
KPG-712 yog ib qho tshiab-tiam me me molecule PDE4 inhibitor nrog kev sib raug zoo rau PDE4 lub hom phiaj, uas tuaj yeem thim rov qab cov cim tshwj xeeb hauv lub cev tiv thaiv kab mob los ntawm inhibiting cyclic adenosine monophosphate (cAMP) hydrolysis hauv lub cev tiv thaiv kab mob, yog li ua tiav lub hom phiaj ntawm kev kho mob. tiv thaiv tus kheej thiab lwm yam kab mob. Raws li lub vev xaib raug cai, KPG-712 tam sim no nyob rau hauv IND-Enabling theem ntawm kev tshaj tawm dual hauv Suav teb thiab Asmeskas.
Tsis tas li ntawd, Kangpu muaj peb lwm cov tshuaj hauv nws cov raj xa dej ntsig txog CRBN E3 ubiquitin ligase complex CRL4CRBN hauv cov kev tshawb fawb ua ntej los tsim kho cov qog hematological, cov qog nqaij hlav thiab lwm yam kab mob.
Los ntawm kev ua kom cov kev kho mob tau zoo ntawm cov haujlwm hauv kev txhim kho thiab ua tiav cov kav dej txuas ntxiv, Kangpu xav tias yuav sau ntau lub tshiab tiam tshiab molecular gel-protein ubiquitination degradation me me molecule tshuaj.
